Telix Pharmaceuticals Limited (TLX)
(Delayed Data from NSDQ)
$10.93 USD
+0.88 (8.76%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $10.92 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TLX 10.93 +0.88(8.76%)
Will TLX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TLX
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Telix Shares May Gain on the Distribution Deal With Cardinal Health
TLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?
What Makes Telix Pharmaceuticals Limited (TLX) a Good Fit for 'Trend Investing'
Other News for TLX
UBS Maintains Buy Rating on TLX, Lowers Target Price to $20 | TLX Stock News
Telix Pharmaceuticals price target lowered by $3 at UBS
Is TLX signaling a buying opportunity? Crossed Above 20 Day Moving Average shows up after rising 0.7%
UBS Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
Telix Pharmaceuticals (TLPPF) Receives a Buy from Morgan Stanley